 Using its proprietary BOLT phage therapy platform, BiomX is developing natural and engineered bacteriophage Phage therapies to treat chronic diseases and cancer. On March 31st announced 2 phage therapy candidates, BX004 and BX005, for cystic fibrosis CF and atopic dermatitis respectively, developed from its BOLT platform now entering Ph. 2 studies. 